Prognostic value of pretreatment serum soluble interleukin-2 receptor levels in primary central nervous system lymphoma: a single-center retrospective study
- 1Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan
Abstract
Primary central nervous system lymphoma (PCNSL) is an aggressive disease with heterogeneous clinical outcomes, and readily measurable prognostic biomarkers remain limited. We retrospectively analyzed 21 patients with newly diagnosed PCNSL who received high-dose methotrexate-based therapy at a single institution between 2006 and 2023. The median age was 68 years, and 12 patients had deep-structure involvement. Median overall survival (OS) and progression-free survival were 41 and 31 months, respectively. In univariate analyses, pretreatment serum soluble interleukin-2 receptor (sIL-2R) level (p = 0.0185), cerebrospinal fluid protein level (p = 0.0401), and receipt of radiotherapy (p = 0.0377) were significantly associated with OS. Receiver operating characteristic analysis of pretreatment serum sIL-2R for 3-year OS yielded an area under the curve of 0.869; a candidate threshold of 566 U/mL showed a sensitivity of 85.7% and specificity of 83.3%. Pretreatment serum sIL-2R was associated with OS in this small retrospective cohort, and this exploratory finding warrants validation in larger independent studies.
Related
- Pretreatment Prognostic Nutritional Index Is Associated with Treatment Response and Survival in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Receiving CAR-T Cell Therapy
- Pretreatment body mass index as a prognostic factor for clinical course and survival in primary surgically treated oral squamous cell carcinoma – a retrospective study
- Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis.
- Survival Outcomes and Prognostic Factors in Elderly Patients with Hodgkin Lymphoma: A Retrospective Cohort Study
- Pretreatment AMH–AFC stratification of poor-ovarian-response risk in young women with diminished ovarian reserve: a multicentre retrospective cohort study
BibTeX
@article{kondo2026prognostic,
title = {{Prognostic value of pretreatment serum soluble interleukin-2 receptor levels in primary central nervous system lymphoma: a single-center retrospective study}},
author = {Kurumi Kondo and Toyotaka Kawamata and Nobuharu Kosugi and Masayuki Kobayashi},
journal = {Clinical Hematology International},
year = {2026},
month = nov,
doi = {10.46989/001c.172867},
url = {https://doi.org/10.46989/001c.172867},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prognostic value of pretreatment serum soluble interleukin-2 receptor levels in primary central nervous system lymphoma: a single-center retrospective study
AU - Kurumi Kondo
AU - Toyotaka Kawamata
AU - Nobuharu Kosugi
AU - Masayuki Kobayashi
PY - 2026
DA - 2026/11/02
JO - Clinical Hematology International
DO - 10.46989/001c.172867
UR - https://doi.org/10.46989/001c.172867
AB - Primary central nervous system lymphoma (PCNSL) is an aggressive disease with heterogeneous clinical outcomes, and readily measurable prognostic biomarkers remain limited. We retrospectively analyzed 21 patients with newly diagnosed PCNSL who received high-dose methotrexate-based therapy at a single institution between 2006 and 2023. The median age was 68 years, and 12 patients had deep-structure involvement. Median overall survival (OS) and progression-free survival were 41 and 31 months, respectively. In univariate analyses, pretreatment serum soluble interleukin-2 receptor (sIL-2R) level (p = 0.0185), cerebrospinal fluid protein level (p = 0.0401), and receipt of radiotherapy (p = 0.0377) were significantly associated with OS. Receiver operating characteristic analysis of pretreatment serum sIL-2R for 3-year OS yielded an area under the curve of 0.869; a candidate threshold of 566 U/mL showed a sensitivity of 85.7% and specificity of 83.3%. Pretreatment serum sIL-2R was associated with OS in this small retrospective cohort, and this exploratory finding warrants validation in larger independent studies.
SN - 2590-0048
ER -